Assertio Therapeutics Company Insiders
ASRT Stock | USD 0.72 0.01 1.41% |
Assertio Therapeutics' insiders are aggressively buying. The analysis of insiders' sentiment of trading Assertio Therapeutics stock suggests that vertually all insiders are extremely bullish at this time. Assertio Therapeutics employs about 58 people. The company is managed by 12 executives with a total tenure of roughly 136 years, averaging almost 11.0 years of service per executive, having 4.83 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
2024-11-18 | Heather L Mason | Acquired 75000 @ 0.8 | View | ||
2024-11-14 | Brendan P O'grady | Acquired 11706 @ 0.85 | View | ||
2024-06-11 | Jeff L Vacirca | Acquired 10000 @ 1.11 | View | ||
2024-06-05 | Heather L Mason | Acquired 25000 @ 0.97 | View |
Monitoring Assertio Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Assertio |
Assertio Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.0453) % which means that it has lost $0.0453 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1666) %, meaning that it created substantial loss on money invested by shareholders. Assertio Therapeutics' management efficiency ratios could be used to measure how well Assertio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.11 in 2025. Return On Capital Employed is likely to drop to -0.15 in 2025. Liabilities And Stockholders Equity is likely to gain to about 335.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 74.2 M in 2025.Common Stock Shares Outstanding is likely to gain to about 100 M in 2025. Net Income Applicable To Common Shares is likely to gain to about 103.6 M in 2025
Assertio Therapeutics Workforce Comparison
Assertio Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 63,625. Assertio Therapeutics adds roughly 58.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Assertio Therapeutics Profit Margins
The company has Profit Margin (PM) of (0.17) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.27) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.27.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 1.3 | 0.6861 |
|
|
Assertio Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Assertio Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Assertio Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Assertio Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
O'grady Brendan P. a day ago Acquisition by Ogrady Brendan P. of 1800000 shares of Assertio Therapeutics at 0.99 subject to Rule 16b-3 | ||
Ajay Patel over a month ago Disposition of 17150 shares by Ajay Patel of Assertio Therapeutics subject to Rule 16b-3 | ||
O'grady Brendan P. over a month ago Acquisition by Ogrady Brendan P. of 500000 shares of Assertio Therapeutics subject to Rule 16b-3 | ||
Mary Pietryga over a month ago Insider Trading | ||
Ajay Patel over a month ago Disposition of 25000 shares by Ajay Patel of Assertio Therapeutics subject to Rule 16b-3 | ||
Staple Peter D over a month ago Acquisition by Staple Peter D of 53750 shares of Assertio Therapeutics subject to Rule 16b-3 | ||
Sam Schlessinger over two months ago Disposition of 19404 shares by Sam Schlessinger of Assertio Therapeutics subject to Rule 16b-3 | ||
Heather Mason over two months ago Acquisition by Heather Mason of 25000 shares of Assertio Therapeutics at 0.97 subject to Rule 16b-3 |
Assertio Therapeutics Notable Stakeholders
An Assertio Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Assertio Therapeutics often face trade-offs trying to please all of them. Assertio Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Assertio Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Brendan OGrady | CEO Director | Profile | |
Heather Mason | Interim Director | Profile | |
Jack Hoblitzell | VP Operations | Profile | |
MD MBA | Senior Medical | Profile | |
Ajay Patel | VP Officer | Profile | |
Sam Schlessinger | Senior Counsel | Profile | |
Molly Dir | Senior Administration | Profile | |
Bill Iskos | Senior Operations | Profile | |
Paul Schwichtenberg | Senior Officer | Profile | |
Jeff Christensen | Senior Commercial | Profile | |
Mary Pietryga | Chief Officer | Profile | |
Daniel Peisert | CEO Pres | Profile |
About Assertio Therapeutics Management Performance
The success or failure of an entity such as Assertio Therapeutics often depends on how effective the management is. Assertio Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Assertio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Assertio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.11) | (0.11) | |
Return On Capital Employed | (0.14) | (0.15) | |
Return On Assets | (0.08) | (0.08) | |
Return On Equity | (0.18) | (0.19) |
Please note, the imprecision that can be found in Assertio Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Assertio Therapeutics. Check Assertio Therapeutics' Beneish M Score to see the likelihood of Assertio Therapeutics' management manipulating its earnings.
Assertio Therapeutics Workforce Analysis
Traditionally, organizations such as Assertio Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Assertio Therapeutics within its industry.Assertio Therapeutics Manpower Efficiency
Return on Assertio Therapeutics Manpower
Revenue Per Employee | 2.2M | |
Revenue Per Executive | 10.4M | |
Net Loss Per Employee | 372.1K | |
Net Loss Per Executive | 1.8M | |
Working Capital Per Employee | 1.5M | |
Working Capital Per Executive | 7.3M |
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.